Therapeutic evaluation of low‐dose IL‐2‐based immunomodulatory approach in patients with early AD
Marie Sarazin, Julien Lagarde, Pauline Olivieri, Virginie Puchois, Laetitia Federici, Thomas Chaigneau, Marie‐Claude Potier, Sylvain Auvity, Michel Bottlaender, Guillaume Dorothée · 2025
Read Therapeutic evaluation of low‐dose IL‐2‐based immunomodulatory approach in patients with early AD by Marie Sarazin, Julien Lagarde, Pauline Olivieri, Virginie Puchois, Laetitia Federici, Thomas Chaigneau, Marie‐Claude Potier, Sylvain Auvity, Michel Bottlaender, Guillaume Dorothée (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11713730.txt.
Description
Marie Sarazin and co-authors set out a trial of low-dose interleukin-2 in early Alzheimer's disease, aiming to calm harmful brain inflammation by strengthening regulatory T cells. Chronic immune activation by microglia and astrocytes helps drive the disease, and T cells talk constantly with the brain's immune system. Small doses of this signaling protein preferentially expand the regulatory cells that keep inflammation in check.
The study evaluates whether that immune rebalancing is safe and shows biological effect in early-stage patients. Prior work in animals and humans supports the strategy. If calming the immune system slows decline, Alzheimer's care gains a gentler lever than amyloid antibodies.
Catalog record
| CREATOR | Marie Sarazin, Julien Lagarde, Pauline Olivieri, Virginie Puchois, Laetitia Federici, Thomas Chaigneau, Marie‐Claude Potier, Sylvain Auvity, Michel Bottlaender, Guillaume Dorothée |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |